ReNeuron Group (AIM: RENE)

Last close As at 22/02/2024


0.00 (0.00%)

Market capitalisation


UK-based ReNeuron Group is focused on its stem cell-derived exosome drug delivery platform, CustomEx. The company is progressing the preclinical development of exosome-based therapeutics utilising its CustomEX technology.

Drug delivery remains a major challenge in both central nervous system (CNS) and cell and gene drug development, and we view these as key markets for ReNeuron to target with its exosome drug delivery platform. Additionally, ReNeuron’s diversification in exosome-producing stem cell lines and its ability to produce exosomes with enhanced natural tissue-targeting affinity, particularly neural stem cell lines to target CNS indications, may offer market differentiation against single cell line competitors.

Latest Insights

View More



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh


Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Ian Ross


  • John Hawkins


  • John Sinden

    Chief Scientific Officer

Balance Sheet

Forecast net cash (£m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (33.8) (36.9) (69.7)
Relative (33.2) (38.8) (68.3)
52 week high/low 11.1p/3.4p


ReNeuron is focused on the development of its stem cell-derived exosome drug delivery platform, CustomEX. In collaboration with academic and industry partners, the company aims to develop novel exosome therapeutics for diseases with significant unmet needs. CustomEX provides a unique delivery mechanism for a variety of therapeutic payloads including nucleic acids, proteins and gene editing technologies. ReNeuron’s exosomes have shown encouraging in vitro data (outside of a biological setting) to deliver such payloads with high tissue specificity. In November 2023, ReNeuron shared new in vivo data (within a biological setting) showing distinct organ/cellular targeting capabilities and the functional delivery of therapeutic payloads.

Y/E Mar Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.4 N/A (11.1) (17.01) N/A N/A
2023A 0.5 N/A (6.7) (9.47) N/A N/A
2024E 0.7 N/A (6.2) (9.14) N/A N/A
2025E 12.1 N/A 4.8 7.18 0.5 0.4

Further insights



Stem cells

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest


Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free